Overview

Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2004-09-29
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining thalidomide with chemotherapy may kill more tumor cells and be an effective treatment for stage IIIB or stage IV non-small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus thalidomide in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest Baptist Health
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Carboplatin
Irinotecan
Thalidomide